Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 583794, 7 pages
http://dx.doi.org/10.1155/2014/583794
Review Article

Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates

1University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
2Regions Hospital, University of Minnesota, 640 Jackson Street, No. 11503C, Saint Paul, MN 55101, USA

Received 12 May 2014; Accepted 25 June 2014; Published 20 July 2014

Academic Editor: Jonathan Douxfils

Copyright © 2014 Lisa M. Baumann Kreuziger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Kazmier, J. A. Spittel, J. J. Thompson, and C. A. Owen, “Effect of oral anticoagulation on factors VII, IX, X, and II,” Archives of Internal Medicine, vol. 115, pp. 667–673, 1965. View at Publisher · View at Google Scholar · View at Scopus
  2. J. van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis & Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. I. Eriksson, D. J. Quinlan, and J. I. Weitz, “Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development,” Clinical Pharmacokinetics, vol. 48, pp. 1–22, 2009. View at Google Scholar
  4. P. C. Wong, D. J. P. Pinto, and D. Zhang, “Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor,” Journal of Thrombosis and Thrombolysis, vol. 31, no. 4, pp. 478–492, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Siegal, D. A. Garcia, and M. A. Crowther, “How I treat target-specific oral anticoagulant-associated homorrhage,” Blood, vol. 123, pp. 1152–1158, 2014. View at Google Scholar
  6. M. R. Southworth, M. E. Reichman, and E. F. Unger, “Dabigatran and postmarketing reports of bleeding,” The New England Journal of Medicine, vol. 368, no. 14, pp. 1272–1274, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. K. M. Bruins Slot and E. Berge, “Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in pateints with atrial fibrillation,” JAMA, vol. 311, pp. 1150–1151, 2014. View at Google Scholar
  8. G. Stepanyan, N. Badhwar, R. J. Lee et al., “Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation,” Journal of Interventional Cardiac Electrophysiology, vol. 40, pp. 33–38, 2014. View at Google Scholar
  9. Baxter, “FEIBA prescribing information,” 2011. View at Google Scholar
  10. CSL Behring GmbH, “Kcentra prescribing information,” http://labeling.cslbehring.com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf.
  11. Novo Nordisk Inc, NovoSeven RT Coagulation Factor VIIa Prescribing Information, 1999.
  12. R. Meehan, M. Tavares, and J. Sweeney, “Clinical experience with oral versus intravenous vitamin K for warfarin reversal (CME),” Transfusion, vol. 53, no. 3, pp. 491–498, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. L. Cracowski, and G. Pernod, “Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers,” Thrombosis and Haemostasis, vol. 108, no. 2, pp. 217–224, 2012. View at Publisher · View at Google Scholar
  14. J. van Ryn, J. Schurer, M. Kink-Eiband, and A. Clemens, “The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation,” Blood, vol. 118, p. 2316, 2011. View at Google Scholar
  15. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Publisher · View at Google Scholar
  16. J. van Ryn, D. Ruehl, H. Priepke, H. Hauel, and W. Wienan, “Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate,” Haematologica, vol. 93, p. 148, 2008. View at Google Scholar
  17. T. Warkentin, P. Margetts, S. Connolly, A. Lamy, C. Ricci, and J. Eikelboom, “Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding,” Blood, vol. 119, pp. 2172–2174, 2012. View at Publisher · View at Google Scholar
  18. S. T. Garber, W. Sivakumar, and R. H. Schmidt, “Neurosurgical complications of direct thrombin inhibitors—catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran,” Journal of Neurosurgery, vol. 116, no. 5, pp. 1093–1096, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Truumees, T. Gaudu, C. Dieterichs, M. Geck, and J. Stokes, “Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on pradaxa (dabigatran),” Spine, vol. 37, pp. E863–E865, 2012. View at Publisher · View at Google Scholar
  20. A. Lillo-Le Louët, M. Wolf, L. Soufir et al., “Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation,” Thrombosis and Haemostasis, vol. 108, no. 3, pp. 583–585, 2012. View at Publisher · View at Google Scholar
  21. S. Schulman, B. Ritchie, J. K. Goy, S. Nahirniak, M. Almutawa, and S. Ghanny, “Activated prothrombin complex concentrate for dabigatran-associated bleeding,” British Journal of Haematology, vol. 164, pp. 296–310, 2013. View at Google Scholar
  22. G. Dickneite and M. Hoffman, “Reversing the new oral anticoagulants with prothrombin comlpex concentrates (PCCs): what is the evidence?” Thrombosis and Haemostasis, vol. 111, no. 2, pp. 189–198, 2014. View at Publisher · View at Google Scholar
  23. G. Escolar, J. Reverter, J. Villalta, V. Sanz, P. Molina, and M. Diaz-Ricart, “Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: Studies in vitro with circulating human blood,” Circulation, vol. 126, p. 521, 2012. View at Google Scholar
  24. D. J. Dries, “The contemporary role of blood products and components used in trauma resuscitation,” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, vol. 18, no. 1, article 63, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Li, J. Hirsh, C. Xie, M. A. Johnston, and J. W. Eikelboom, “Reversal of the anti-platelet effects of aspirin and clopidogrel,” Journal of Thrombosis and Haemostasis, vol. 10, no. 4, pp. 521–528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Thiele, A. Sümnig, G. Hron et al., “Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study,” Journal of Thrombosis and Haemostasis, vol. 10, pp. 968–971, 2012. View at Publisher · View at Google Scholar
  27. Janssen Pharmaceuticals Inc, “Xarelto prescribing information,” 2011.
  28. Bristol-Myers Squibb, “Eliquis (apixiban) prescribing information,” 2012, http://packageinserts.bms.com/pi/pi_eliquis.pdf.
  29. L. M. Baumann Kreuziger and M. T. Reding, “Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices,” Thrombosis Research, vol. 132, no. 2, pp. e161–e163, 2013. View at Publisher · View at Google Scholar
  30. M. E. Kutcher, B. J. Redick, R. C. McCreery et al., “Characterization of platelet dysfunction after trauma,” Journal of Trauma and Acute Care Surgery, vol. 73, pp. 13–19, 2012. View at Google Scholar
  31. D. Bolliger, M. D. Seeberger, and K. A. Tanaka, “Principles and practice of thromboelastography in Clinical Coagulation Management and Transfusion Practice,” Transfusion Medicine Reviews, vol. 26, no. 1, pp. 1–13, 2012. View at Publisher · View at Google Scholar
  32. V. A. Ferraris, A. C. Bernard, B. Hyde, and P. A. Kearney, “The impact of antiplatelet drugs on trauma outcomes,” Journal of Trauma and Acute Care Surgery, vol. 73, no. 2, pp. 492–497, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Joseph, V. Pandit, M. Sadoun et al., “A prospective evaluation of platelet function in patients on antiplatelet therapy with traumatic intracranial hemorrhage,” Journal of Trauma and Acute Care Surgery, vol. 75, pp. 900–994, 2013. View at Google Scholar
  34. D. K. Nishijima, S. Zehtabchi, J. Berrong, and E. Legome, “Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review,” Journal of Trauma and Acute Care Surgery, vol. 72, pp. 1658–1663, 2012. View at Publisher · View at Google Scholar
  35. J. N. Harr, E. E. Moore, J. Johnson et al., “Antiplatelet therapy is not associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients,” Critical Care Medicine, vol. 41, pp. 399–404, 2013. View at Publisher · View at Google Scholar
  36. K. A. Peck, R. Y. Calvo, M. S. Schechter et al., “The impact of preinjury anticoagulants and prescription antiplatelet agents on outcomes in older patients with traumatic brain injury,” Journal of Trauma and Acute Care Surgery, vol. 76, pp. 431–436, 2014. View at Publisher · View at Google Scholar
  37. J. L. Gordon, T. C. Fabian, M. D. Lee, and M. Dugdale, “Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies,” The Journal of Trauma and Acute Care Surgery, vol. 75, no. 3, pp. 475–486, 2013. View at Publisher · View at Google Scholar
  38. M. D. Lambourne, L. J. Eltringham Smith, S. Gataiance, D. M. Arnold, M. A. Crowther, and W. P. Sheffield, “Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate,” Journal of Thrombosis and Haemostasis, vol. 10, no. 9, pp. 1830–1840, 2012. View at Publisher · View at Google Scholar
  39. I. Pragst, S. H. Zeitler, B. Doerr et al., “Reversal of dabigatran anticoagulation by prothrombin complex concentrate (beriplex P/N) in a rabbit model,” Journal of Thrombosis and Haemostasis, vol. 10, no. 9, pp. 1841–1848, 2012. View at Publisher · View at Google Scholar
  40. W. Zhou, S. Schwarting, S. Illanes et al., “Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran,” Stroke, vol. 42, pp. 3594–3599, 2011. View at Publisher · View at Google Scholar
  41. T.-L. Khoo, C. Weatherburn, G. Kershaw, C. J. Reddel, J. Curnow, and S. Dunkley, “The use of FEIBA in the correction of coagulation abnormalities induced by dabigatran,” International Journal of Laboratory Hematology, vol. 35, no. 2, pp. 222–224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. K. Wychowski and P. Kouides, “Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment,” Annals of Pharmacotherapy, vol. 46, no. 4, article e10, 2012. View at Publisher · View at Google Scholar
  43. L. E. Dumkow, J. R. Voss, M. Peters, and D. L. Jennings, “Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma,” American Journal of Health-System Pharmacy, vol. 69, no. 19, pp. 1646–1650, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Perzborn and H. Tinel, “Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats,” Journal of Thrombosis and Haemostasis, vol. 7, article 183, 2009. View at Google Scholar
  45. A. Godier, A. Miclot, B. Le Bonniec et al., “Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model,” Anesthesiology, vol. 116, pp. 94–102, 2012. View at Google Scholar
  46. E. Perzborn, A. Gruber, H. Tinel et al., “Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates,” Thrombosis and Haemostasis, vol. 110, no. 1, pp. 162–172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Dinkelaar, P. J. Molenaar, M. Ninivaggi, B. de Laat, H. J. M. Brinkman, and A. Leyte, “In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban,” Journal of Thrombosis and Haemostasis, vol. 11, no. 6, pp. 1111–1118, 2013. View at Publisher · View at Google Scholar
  48. M. Körber, E. Langer, S. Ziemer, E. Perzborn, C. Gericke, and C. von Heymann, “Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study,” Clinical and Applied Thrombosis/Hemostasis, 2013. View at Publisher · View at Google Scholar